Spravato Approved for Treatment-Resistant Depression
ADDitude
FEBRUARY 24, 2025
February 25, 2025 Spravato, the esketamine nasal spray approved in 2019 for use alongside oral antidepressants for treatment-resistant depression, has been approved by the U.S. Esketamine is a form of the dissociative agent ketamine , commonly used as an anesthetic; it works by targeting the neurotransmitter glutamate.
Let's personalize your content